As the industry prepares for the next wave of healthcare interoperability, the HL7 Da Vinci Project is dedicated to providing the community with the insights and tools necessary for success. With newly proposed regulatory frameworks, the stakes for technical and operational alignment have never been higher. Join us for the May Community Roundtable on Wednesday, May 27, 2026, from 4 – 5:30 p.m. ET to prepare for what’s next.
While our April session established the foundational context for the new federal rule (CMS-0062-P), the May session builds on the momentum by moving from initial impressions to active implementation strategies. We will provide a focused update of the community’s considerations regarding the 2026 Interoperability Standards and Prior Authorization for Drugs proposed rule, specifically focusing on the Payer Data Exchange (PDex), PDex Plan Net, and Member Attribution (ATR) List Implementation Guides (IGs) called out in the rule.
Following the policy discussion, you will hear directly from implementers successfully deploying these standards in real-world payer environments:
Our presenters will share critical insights on scalability and how these implementations support broader policy goals around data access, care coordination, and patient empowerment.
📅 Date: Wednesday, May 27, 2026
🕓Time: 4 - 5:30 p.m. ET
💻 Location: Virtual (Free & open to the public)
🔗Register here: https://zoom.us/webinar/register/WN_Oj7An7OLR_67YN630XCILQ
We highly encourage you to review last month’s session recording to ensure you have the necessary context for this month's deep dive.
The HL7 Da Vinci Project hosts monthly Community Roundtables to share real-world FHIR implementation experiences, highlight lessons learned, and foster collaboration across the healthcare ecosystem. These sessions accelerate the adoption of HL7 FHIR standards to achieve scalable, actionable interoperability. Sessions are recorded and available online after the event.
Learn more about the HL7 Da Vinci Project and join the community by following us on LinkedIn.